%0 Journal Article
%T Effectiveness of Istradefylline for Fatigue and Quality of Life in Parkinson¡¯s Disease Patients¡¯ and of Their Caregivers¡¯
%A Kazuo Abe
%A Masashi Fujita
%A Hiroo Yoshikawa
%J Advances in Parkinson's Disease
%P 24-28
%@ 2169-9720
%D 2016
%I Scientific Research Publishing
%R 10.4236/apd.2016.52004
%X Objectives: We evaluated efficacy and safety of istradefylline that is the first selective adenosine
A2A receptor antagonist, for the treatment of non-motor symptoms and quality of life (QoL) in
Parkinson¡¯s disease (PD) patients with and QoL in their caregivers. Methods: This was a multisites
study of 40 PD patients (female 24, male 16) who fully filled UK PD society brain bank clinical
diagnostic criteria. They received istradefylline 20 mg/day for 8 weeks. We added istradefylline
on the previous anti-Parkinson¡¯s drugs. Clinical severities were evaluated by Hoehn-Yahr (H-Y)
stage, unified PD rating scale (UPDRS), non-motor symptoms in PD (NMSPD), fatigue severity scale
(FSS) and Euro QoL. Also, we evaluated their caregiver¡¯s QoL by Euro QoL. Results: The scores of
UPDRS part I improved from 1.3 ¡À 1.1 to 06 ¡À 0.9 (P = 0.18), part II improved from 11.9 ¡À 3.2 to
11.0 ¡À 3.1 (P = 0.17), part III improved from 34.8 ¡À 7.2 to 32.1 ¡À 8.3 (P = 0.105). There was no significant
improvement or worsening of the H-Y stages. The scores of NMSPD improved from 49.9 ¡À
11.2 to 43.9 ¡À 10.6 (P = 0.08). The scores of FSS improved from 62.8 ¡À 7.1 to 52.3 ¡À 9.3 (P = 0.049).
The total scores of Euro QoL in PD patients improved from 48.8 ¡À 14.9 to 57.2 ¡À 13.0 (P = 0.045).
The total scores of Euro QoL in patients¡¯ caregivers improved from 54.2 ¡À 11.0 to 59.8 ¡À 10.9 (P =
0.046). Conclusions: Our data demonstrated that istradefylline was associated with few side effects
and was modestly effective for the treatment of non-motor symptoms especially fatigue that
might improve QoL in PD patients as well as in their caregivers¡¯.
%K Parkinson¡¯s Disease
%K Non-Motor Symptoms
%K Istradefylline
%K Fatigue
%K Quality of Life
%K Caregivers
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=66515